Example: Heart Attack

Search clinical trials for: TAS-102

Total 52 results

NCT05064059

Recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Conditions: Colorectal Cancer
NCT05364489

Not yet recruiting

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Conditions: Advanced Colorectal Cancer
NCT05328908

Recruiting

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Conditions: Colorectal Neoplasms
NCT05343013

Not yet recruiting

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Conditions: Colorectal Cancer
NCT04701476

Recruiting

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Conditions: Colorectal Cancer; Lung Cancer
NCT03974594

Completed

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Conditions: Colorectal Cancer
NCT05314101

Not yet recruiting

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Conditions: Immunotherapy, Colorectal Cancer
NCT04074343

Active, not recruiting

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Conditions: Gastric Adenocarcinoma, GastroEsophageal Cancer
NCT05266820

Recruiting

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer
NCT03762161

Recruiting

A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Conditions: Bladder Cancer
NCT04517747

Active, not recruiting

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction

Conditions: Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction
NCT03686488

Active, not recruiting

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
NCT03297710

Completed

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Conditions: Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
NCT03520946

Recruiting

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Conditions: Colorectal Cancer
NCT05029102

Recruiting

TAS-102 and Anlotinib in ≥3 Lines mGC

Conditions: Gastric Cancer
NCT04776148

Active, not recruiting

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Conditions: Colorectal Neoplasms
NCT02920476

Completed

TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

Conditions: Squamous Cell Lung Carcinoma
NCT02943733

Active, not recruiting

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Conditions: Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
NCT05004831

Not yet recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Conditions: Metastatic Colorectal Cancer
NCT03278106

Active, not recruiting

TAS-102 in Treating Advanced Biliary Tract Cancers

Conditions: Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVB Gallbladder Cancer AJCC v7
NCT04868773

Recruiting

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Conditions: Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer, CRC
NCT04920032

Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Conditions: Colon Adenocarcinoma, Colorectal Cancer
NCT02500043

Completed

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Conditions: Refractory Metastatic Gastric Cancer
NCT02602327

Active, not recruiting

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Conditions: Colon Cancer, Rectal Cancer, Liver Metastases
NCT02860546

Completed

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Conditions: Refractory Metastatic Colorectal Cancer

Search clinical trials for: TAS-102

Medical Conditions

Sponsors and Collaborators

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations